News

Neurocrine refines INGREZZA net sales guidance to $2.5B-$2.55B while CRENESSITY surges, driving revenue growth and pipeline expansion
Discover key insights from Neurocrine Biosciences' Q2 2025 earnings, featuring record INGREZZA growth, CRENESSITY's rapid adoption, and strategic ...